Form 4: uniQure Director Robert Gut Receives Equity Grants Valued at Over $250,000

uniQure N.V. Director Robert Gut was granted 7,970 restricted share units and stock options for 15,630 ordinary shares, as disclosed in a recent SEC Form 4 filing.

Summary

• Robert Gut, a Director at uniQure N.V. (QURE), acquired 7,970 Ordinary Shares in the form of Restricted Share Units (RSUs) on June 11, 2025.
• These RSUs were granted under the Issuer's 2014 Share Incentive Plan and represent the contingent right to receive one Ordinary Share per unit.
• The RSUs vest 100% on the first anniversary of the grant date, contingent on Mr. Gut's continued relationship with uniQure.
• Additionally, Mr. Gut was granted stock options to purchase 15,630 Ordinary Shares on June 11, 2025, with an exercise price of $16.22 per share.
• These stock options also vest 100% on the first anniversary of the grant date, subject to Mr. Gut's continued relationship with the Issuer.
• The stock options have an expiration date of June 11, 2035.
• Following these transactions, Mr. Gut beneficially owns 60,215 Ordinary Shares directly and 15,630 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event, indicating continued alignment of a director's interests with the company, but does not provide new operational or financial performance insights.

Positives

• The grants of Restricted Share Units and stock options serve as a form of equity compensation, aligning the director's interests with long-term shareholder value.
• The vesting schedule encourages the director's continued commitment and relationship with uniQure N.V.

Future Outlook

The document indicates future vesting of equity awards for Director Robert Gut, contingent on his continued relationship with uniQure N.V. through the first anniversary of the grant date (June 11, 2026). The stock options are exercisable until June 11, 2035.

Industry Context

This Form 4 filing is a routine disclosure of equity compensation for a director in the biotechnology industry. Such grants are common practice to attract and retain executive talent and align their incentives with company performance, consistent with compensation strategies across the sector.

Comparison to Industry Standards

• The granting of Restricted Share Units (RSUs) and stock options as part of director compensation is a standard practice across the biotechnology and pharmaceutical industries, similar to companies like BioNTech, Moderna, or Regeneron, which frequently use equity awards to incentivize and retain key personnel.
• The vesting schedule (100% on the first anniversary) is a common short-to-medium term incentive structure, though multi-year vesting schedules are also prevalent in the industry for long-term retention.

Related Party Transactions

• The grant of Restricted Share Units and stock options to Director Robert Gut constitutes a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grants represent a form of compensation that aligns the director's interests with shareholder value, but also involves potential future dilution upon vesting and exercise.
• Employees: While specific to a director, such compensation practices can reflect broader company policies on equity incentives, potentially impacting employee morale and retention strategies.

Next Steps

• The Restricted Share Units and stock options granted to Robert Gut are scheduled to vest on June 11, 2026, subject to his continued relationship with uniQure N.V.

Key Dates

Keywords

uniQure N.V., QURE, SEC Form 4, Insider Transaction, Restricted Share Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, Biotechnology, Pharmaceuticals